KANEKA CORPORATION FY2027 Q1 Earnings Report

Quick View

Executive Summary

The key feature of the quarter was higher revenue and earnings, with Operating Income expanding significantly on the back of improved gross margin and greater cost efficiency. Revenue was ¥2,230.2B (+12.3% YoY), Operating Income was ¥149.4B (+83.1%), Ordinary Income was ¥137.5B (+127.7%), and Net Income was ¥95.0B (+106.6%). The gross margin improved to 29.4% (27.3% in the previous year), while the SG&A ratio declined to 22.7% (23.2% in the previous year), resulting in a structure in which earnings grew more rapidly than revenue.

Factors Affecting Performance

【Revenue】Revenue was ¥2,230.2B, up +12.3% YoY. By segment, Material Solutions (¥945.5B, +14.7%) posted the largest absolute increase, while Health Care Solutions (¥220.3B, +20.4%) recorded the highest growth rate. Quality of Life Solutions (¥538.8B, +11.1%) and Nutrition Solutions (¥524.5B, +6.3%) also contributed to revenue growth, resulting in broad-based growth across all four businesses.

【Profit and Loss】Operating Income was ¥149.4B (+83.1%), driven by both a +2.1pt improvement in gross margin and a -0.5pt improvement in the SG&A ratio. In terms of segment profit, Material Solutions (¥108.6B, +73.3%) posted the largest increase, while Quality of Life (¥70.1B, +34.5%) also achieved strong growth. Ordinary Income was ¥137.5B (+127.7%). Although non-operating expenses of ¥25.8B, including ¥10.9B in interest expenses, exceeded non-operating income of ¥13.9B, including ¥6.8B in dividend income and ¥3.4B in foreign exchange gains, the increase in Operating Income more than offset the difference. Extraordinary losses were ¥3.3B, including losses on the disposal of fixed assets, and the impact of one-time factors was limited. Net Income was ¥95.0B (+106.6%), resulting in higher revenue and earnings.

Segment Analysis

By segment, Material Solutions, with Revenue of ¥945.5B (+14.7%) and Operating Income of ¥108.6B (+73.3%), was the largest contributor to the increase in profit in absolute terms. Profit margins were relatively high in Health Care Solutions (15.8%) and Quality of Life Solutions (13.0%), while Nutrition Solutions (6.4%) continued to grow but had a lower profit margin than the other segments. Company-wide expenses, primarily basic research and development expenses, were recorded as a negative adjustment of ¥99.1B, accounting for the difference between total segment profit of ¥248.6B and consolidated Operating Income of ¥149.4B.

Key Financial Metrics

【Profitability】The Operating Income margin improved by +2.6pt to 6.7% (4.1% in the previous year), while the Net Income margin expanded to 4.3% (2.3% in the previous year). The gross margin improved to 29.4% (27.3% in the previous year), indicating progress in pricing, product mix, and cost efficiency.【Cash Flow Quality】Extraordinary losses were limited to ¥3.3B, and recurring earnings improvement was the primary driver of the increase in profit.【Investment Efficiency】ROE remained low at 1.8%; as indicated by the ratio of Net Income of ¥95.0B to total assets of ¥9,830.1B, low capital turnover remains a constraint. EPS improved significantly to ¥148.46 (¥67.74 in the previous year).【Financial Soundness】The Equity Ratio remained broadly unchanged at 53.7% (54.4% in the previous year), indicating a stable capital structure.

Cash Flow Analysis

As cash flow statement data has not been disclosed, funding trends are analyzed based on changes in the balance sheet. Inventories were ¥1,176.2B, an increase of +¥68.5B from the previous year, while accounts receivable and notes receivable remained high at ¥1,627.6B, indicating an accumulation of working capital associated with higher revenue. Meanwhile, accounts payable and notes payable increased by +¥70.0B to ¥880.0B, partially offsetting working capital requirements. Short-term borrowings increased by +¥139.4B to ¥1,534.7B, suggesting that the increase in working capital was financed through short-term funding. Cash and deposits were ¥525.8B, representing only a modest +3.1% YoY increase, and the accumulation of cash on hand was limited relative to the pace of increase in short-term liabilities.

Earnings Quality

Extraordinary losses, including losses on the disposal of fixed assets, were ¥3.3B, a small proportion of Net Income, and the impact of one-time factors on performance was limited. Non-operating income was ¥13.9B, including ¥6.8B in dividend income and ¥3.4B in foreign exchange gains, while non-operating expenses were ¥25.8B, including ¥10.9B in interest expenses. Both remained below 1% of Revenue, indicating that changes in recurring earnings power led the increase in profit for the period. Comprehensive Income was ¥111.3B, and the difference from Net Income of ¥95.0B was primarily attributable to a ¥20.7B increase in foreign currency translation adjustments, reflecting the contribution from the valuation of overseas assets and businesses. The gap between Ordinary Income and Net Income was limited to corporate income taxes of ¥39.2B and profit attributable to non-controlling interests of ¥5.5B, with no particular abnormalities observed.

Earnings Forecast and Guidance

Progress against the full-year plan was 27.2% for Revenue (¥2,230.2B out of ¥8,200.0B), 41.5% for Operating Income (¥149.4B out of ¥360.0B), and 42.9% for Ordinary Income (¥137.5B out of ¥320.0B). Compared with the simple one-quarter benchmark of 25%, progress is particularly advanced on the earnings front. If the pace of margin improvement in Q1 continues through the second half of the fiscal year, the results suggest potential upside relative to the full-year plan. The Company has not revised its earnings forecast and is maintaining a conservative stance at this point.

Shareholder Returns

The Company’s full-year dividend forecast is ¥210 (¥80 in the previous year), implying a Payout Ratio of approximately 40.1% based on the initial-period EPS plan of ¥523.04. No revision has been made to the dividend forecast. Given the strong earnings progress in the current quarter, the policy of increasing the full-year dividend remains consistent; however, if the trend of increasing working capital continues, balancing the retention of internal reserves may become an issue going forward.

Risk Factors

1. Accumulation of working capital: Inventories of ¥1,176.2B and accounts receivable and notes receivable of ¥1,627.6B remain high, and cash absorption associated with higher revenue is continuing. Progress in collections and inventory reduction will determine future cash generation capacity.

2. Dependence on short-term funding: Against short-term borrowings of ¥1,534.7B, cash and deposits are ¥525.8B, leaving a cash coverage ratio against short-term liabilities of approximately 34%. The funding structure is tilted toward short-term financing, creating sensitivity to changes in the interest-rate environment.

3. Low capital efficiency: ROE is 1.8%, indicating low capital turnover relative to the level of profit generated on total assets of ¥9,830.1B. Whether the earnings growth phase continues will be key to improving capital efficiency going forward.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Company’s profit margins are below the industry median, placing it in the lower-middle tier of the industry in terms of profitability.

Growth and Capital Efficiency

The Revenue growth rate is significantly above the industry median, placing the Company in the industry’s upper group.

※Source: Compiled by the Company

Key Takeaways from the Results

1. The structure in which the earnings growth rate significantly exceeded the revenue growth rate, supported by improved gross margin (+2.1pt) and a lower SG&A ratio (-0.5pt), enhanced the quality of the results through operating leverage.

2. Progress in earnings against the full-year plan (41.5% for Operating Income) exceeded progress in revenue (27.2%), making the sustainability of the Q1 margin improvement a key focus going forward.

3. Inventories and accounts receivable increased in parallel with greater dependence on short-term borrowings. The continued absorption of funds by working capital behind the earnings growth requires monitoring from the perspective of cash generation capacity.

Theoretical Share Price (Reference Value)

Sensitivity: ¥7,853–¥8,309 at ±1% for the cost of equity, and ¥8,053–¥8,092 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value will be below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---